Skip to content Skip to content

Press Releases


Filter Releases
 
INCLINE VILLAGE, Nev., Dec. 17, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the closing of the previously announced acquisition of substantially all of LENSAR, Inc.'s (LENSAR) assets by a wholly-owned subsidiary of ALPHAEON Corporation. As part of this acquisition, ALPHAEON's subsidiary entered into an amended and ...
INCLINE VILLAGE, Nev., Dec. 14, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the December 11, 2015, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of December 4, 2015, the record date. About PDL BioPharmaPDL manages a portfolio of patents an...
INCLINE VILLAGE, Nev., Dec. 2, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today acknowledges receipt of $133.7 million in notable cash payments from November 1, 2015 through December 1, 2015. PDL does not typically report individual payments such as these, but given the interest relating to some of these payments, the company dec...
INCLINE VILLAGE, Nev., Nov. 24, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 27th Annual Piper Jaffray Healthcare Conference next week in New York City. The presentation will be webcast live and will occur on Tuesday, D...
INCLINE VILLAGE, Nev., Nov. 16, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced recent developments related to its debt investment in LENSAR, Inc. (LENSAR), a leading global developer and manufacturer of Femtosecond Cataract Lasers.  As announced by ALPHAEON Corporation (ALPHAEON), a definitive agreement between a subs...
INCLINE VILLAGE, Nev., Nov. 11, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Jefferies Autumn 2015 Global Healthcare Conference in London, England.  The presentation will be webcast live and will occur on Wednesday, Nov...
INCLINE VILLAGE, Nev., Nov. 6, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) issued financial results for the third quarter on Wednesday, November 4, 2015 and has subsequently received numerous inquiries on its reported royalties from royalty rights it acquired from Depomed, Inc. (Depomed).  Specifically, the nature of the questions...
INCLINE VILLAGE, Nev., Nov. 4, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the third quarter and nine months ended September 30, 2015. Total revenues were $124.6 million for the three months ended September 30, 2015, compared to $164.6 million for the same period of 2014, and $412.4 mil...
INCLINE VILLAGE, Nev., Oct. 28, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL, or the Company) (NASDAQ: PDLI) today announced that the Company will release its third quarter 2015 financial results for the period ended September 30, 2015, on Wednesday, November 4, 2015, after market close. PDL's management will host a conference call and webcast tha...
INCLINE VILLAGE, Nev., Sept. 23, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that PDL has received approximately $21.4 million in connection with the termination of PDL's structured financing agreement with Avinger, Inc. (NASDAQ: AVGR), which included repayment of the full principal amount outstanding of $20.6 mill...
INCLINE VILLAGE, Nev., Sept. 21, 2015 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (Nasdaq: PDLI) announced today that it has acquired a portion of the royalties on expected sales of AcelRx Pharmaceuticals Inc.'s ("AcelRx") (Nasdaq: ACRX) Zalviso™ (sufentanil sublingual tablet system) in the European Union, Switzerland and Australia by its com...
INCLINE VILLAGE, Nev., Sept. 16, 2015 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) today announced that Samuel R. Saks, M.D. has been appointed to the company's board of directors. Dr. Saks serves as a board member for several biotechnology and pharmaceutical companies. Dr. Saks brings over 35 years of biotechnology management ...
INCLINE VILLAGE, Nev., Sept. 14, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the September 11, 2015, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of September 4, 2015, the record date. About PDL BioPharma PDL manages a portfolio of patent...
INCLINE VILLAGE, Nev., Sept. 10, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 6th Annual Credit Suisse US Small & Mid Cap Conference in New York City next week. The group presentation will occur on Thursday, September 1...
INCLINE VILLAGE, Nev., Sept. 8, 2015 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) today announced that Paul R. Edick has been appointed to the company's board of directors. Mr. Edick is currently managing partner of 3G Advisors, LLC, a consultancy to the pharmaceutical, healthcare and healthcare investor communities. Mr. Edick ...
= add release to Briefcase